Ionis Pharmaceuticals vs Sarepta Therapeutics
Ionis holds the stronger position because its approved drug lineup keeps growing revenue fast while facing less risk of a giant simply copying its approach, whereas Sarepta's main growth product has run into safety and approval problems that open the door to rivals.
Ionis Pharmaceuticals
Ionis makes RNA-targeting drugs (antisense) for rare and cardiometabolic disease
Sarepta Therapeutics
Gene therapy maker selling ELEVIDYS and PMO drugs for Duchenne muscular dystrophy
Dimension by dimension
| Dimension | Ionis Pharmaceuticals | Sarepta Therapeutics |
|---|---|---|
| Staying power of the core product | Ionis sells several approved antisense drugs and revenue keeps climbing across quarters, with FY2025 revenue up 33.8 percent and Q1 2026 revenue up about 87 percent year over year. | Sarepta's growth product ELEVIDYS ran into safety scares and an EU rejection, and its older PMO drugs still make up more than half of its revenue. |
| Exposure to AI absorbing the product | Unlikely, since Ionis makes physical drugs that AI cannot substitute. | Unlikely, since Sarepta also makes physical gene therapies that AI cannot substitute. |
| How easily a giant could copy them | Blocked, meaning Ionis's antisense drug approach is harder for a large company to simply replicate. | Possible, meaning a larger company could more plausibly build a competing version of Sarepta's approach. |
| Pressure from rivals | Alnylam is gaining ground in ATTR cardiomyopathy and RNA-based drugs after Ionis had a cardiovascular trial setback. | No direct customer defections yet, but ELEVIDYS safety scares and the EU rejection have opened exon-51 DMD patients to Dyne Therapeutics, REGENXBIO, and Solid Biosciences. |
| Financial footing | Ionis posted $943.7 million in FY2025 revenue and $1.06 billion trailing twelve month revenue, both growing at double digit or higher rates. | Sarepta posted $1.864 billion in full year 2025 net product revenue, larger in absolute terms but split between a shaky growth product and a steadier older line. |
| Overall standing | Ionis is rated protection under test, reflecting a mixed but not deteriorating position. | Sarepta is rated losing its protection, reflecting active safety and approval setbacks. |
Questions people ask
- Ionis Pharmaceuticals vs Sarepta Therapeutics, which is better positioned for the AI era
- Neither company faces meaningful AI exposure since both sell physical drugs, so the comparison comes down to product stability and competitive pressure. Ionis is rated protection under test while Sarepta is rated losing its protection due to ELEVIDYS safety scares and an EU rejection. On that basis Ionis currently holds the stronger position.
- Does AI threaten Ionis or Sarepta's drugs
- No, AI absorption is rated unlikely for both Ionis and Sarepta since their products are physical antisense and gene therapies that AI cannot replace.
- Which company is more at risk from competitors, Ionis or Sarepta
- Both face real rival pressure. Ionis is losing ground to Alnylam in ATTR cardiomyopathy and RNA-based drugs after a cardiovascular trial setback, while Sarepta faces new competition from Dyne Therapeutics, REGENXBIO, and Solid Biosciences after ELEVIDYS ran into safety concerns and an EU rejection.
- How do Ionis and Sarepta compare on revenue growth
- Ionis reported FY2025 revenue of $943.7 million, up 33.8 percent year over year, and Q1 2026 revenue up about 87 percent year over year. Sarepta reported larger full year 2025 net product revenue of $1.864 billion, but its growth driver ELEVIDYS has been clouded by safety and approval setbacks.
- Could a larger company copy Ionis or Sarepta's approach
- Ionis's antisense drug approach is rated blocked, meaning it is harder for a giant to copy. Sarepta's gene therapy approach is rated possible, meaning a larger company could more plausibly build a competing version.
Other comparisons with these companies